{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:53:39Z","timestamp":1761166419221,"version":"build-2065373602"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Graphics and Modelling"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jmgm.2017.08.019","type":"journal-article","created":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T09:00:36Z","timestamp":1503565236000},"page":"205-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Investigating detailed interactions between novel PAR1 antagonist F16357 and the receptor using docking and molecular dynamic simulations"],"prefix":"10.1016","volume":"77","author":[{"given":"Carolyn","family":"Readmond","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmgm.2017.08.019_bib0005","doi-asserted-by":"crossref","first-page":"775","DOI":"10.5604\/17322693.1209209","article-title":"Protease-activated receptors \u2212 biology and role in cancer","volume":"70","author":"Hempel","year":"2016","journal-title":"Postepy Hig. Med. Dosw."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/15216540213469","article-title":"Protease-activated receptors: a means of converting extracellular proteolysis into intracellular signals","volume":"53","author":"Mackie","year":"2002","journal-title":"IUBMB Life"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0015","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2174\/0929867023369934","article-title":"Thrombin receptor antagonists; Recent advances in PAR-1 antagonist development","volume":"9","author":"Anderluh","year":"2002","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.pharmthera.2011.01.003","article-title":"Structure, function and pathophysiology of protease activated receptors","volume":"130","author":"Adams","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0025","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/SHK.0b013e3182507774","article-title":"Inhibition of proinflammatory cytokines by SCH79797, a selective protease-activated receptor 1 antagonist, protects rat kidney against ischemia-reperfusion injury","volume":"37","author":"El Eter","year":"2012","journal-title":"Shock"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0030","doi-asserted-by":"crossref","first-page":"34788","DOI":"10.18632\/oncotarget.5858","article-title":"PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway","volume":"6","author":"Fujimoto","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0035","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.2174\/1568026615666150519103911","article-title":"From multiple PAR1 Receptor\/Protein interactions to their multiple therapeutic implications","volume":"15","author":"Gutierrez-Rodriguez","year":"2015","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0040","first-page":"507","article-title":"Protease-Activated receptors: activation, inhibition and pharmaceutical relevance","volume":"109","author":"Jindrova","year":"2015","journal-title":"Chem. Listy"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0045","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.brainresrev.2007.08.002","article-title":"Protease-activated receptors in the brain: receptor expression, activation, and functions in neurodegeneration and neuroprotection","volume":"56","author":"Luo","year":"2007","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.18632\/oncotarget.211","article-title":"The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis \u2212 a possible therapeutic target","volume":"2","author":"Villares","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0055","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2174\/1381612033453884","article-title":"Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis an inflammatory diseases","volume":"9","author":"Ahn","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0060","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1517\/13543784.12.2.209","article-title":"Therapeutic potential of protease-activated receptor-1 antagonists","volume":"12","author":"Derian","year":"2003","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0065","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00281-011-0281-9","article-title":"The roles of thrombin and protease-activated receptors in inflammation","volume":"34","author":"Ma","year":"2012","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0070","doi-asserted-by":"crossref","first-page":"472","DOI":"10.2174\/1381612822666151222160933","article-title":"The role of protease-Activated receptors for the development of myocarditis: possible therapeutic implications","volume":"22","author":"Weithauser","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0075","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/bph.13501","article-title":"F16357, a novel protease-activated receptor 1 antagonist, improves urodynamic parameters in a rat model of interstitial cystitis","volume":"173","author":"Monjotin","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0080","first-page":"10","article-title":"Macrophage migration inhibitory factor mediates PAR-Induced bladder pain","volume":"1","author":"Kouzoukas","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0085","doi-asserted-by":"crossref","first-page":"e15904","DOI":"10.1371\/journal.pone.0015904","article-title":"Thrombin induces macrophage migration inhibitory factor release and upregulation in urothelium: a possible contribution to bladder inflammation","volume":"5","author":"Vera","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0090","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2146\/ajhp140758","article-title":"Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease","volume":"72","author":"Arif","year":"2015","journal-title":"Am. J. Health. Syst. Pharm."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0095","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3909\/ricm0754","article-title":"A novel inhibitor of protease-activated receptor 1: a review of chemical structure and mode of action","volume":"16","author":"Hashemzadeh","year":"2015","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0100","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.blre.2014.10.006","article-title":"Approval of the first protease-activated receptor antagonist: rationale, development, significance, and considerations of a novel anti-platelet agent","volume":"29","author":"French","year":"2015","journal-title":"Blood Rev."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0105","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-015-0387-9","article-title":"Vorapaxar a review of its use in the long-Term secondary prevention of atherothrombotic events","volume":"75","author":"Frampton","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0110","first-page":"3801","article-title":"Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar","volume":"9","author":"Farag","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5482\/HAMO-12-05-0006","article-title":"Vorapaxar expands antiplatelet options Which patients may benefit from thrombin receptor antagonism?","volume":"32","author":"Duerschmied","year":"2012","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0120","first-page":"1133","article-title":"Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis","volume":"11","author":"Diehl","year":"2015","journal-title":"Ther. Clin. Risk Manage."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0125","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/1060028015571410","article-title":"Vorapaxar in atherosclerotic disease management","volume":"49","author":"Cheng","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0130","doi-asserted-by":"crossref","first-page":"387-","DOI":"10.1038\/nature11701","article-title":"High-resolution crystal structure of human protease-activated receptor 1","volume":"492","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0135","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40119-013-0013-4","article-title":"Thrombin receptor antagonism in antiplatelet therapy","volume":"2","author":"Olivier","year":"2013","journal-title":"Cardiol. Ther."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1742-7843.2007.00078.x","article-title":"Protease-Activated receptor 1-Selective antagonist SCH79797 inhibits cell proliferation and induces apoptosis by a protease-Activated receptor 1-Independent mechanism","volume":"101","author":"Di Serio","year":"2007","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0145","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/10428194.2016.1190977","article-title":"Efficacy, safety, and dose adjustment of cyclophosphamide in lymphoma patients requiring hemodialysis","volume":"58","author":"Hamadah","year":"2017","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejca.2016.10.035","article-title":"Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide","volume":"71","author":"Jamieson","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0155","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/10428194.2016.1190966","article-title":"FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia","volume":"58","author":"Kutsch","year":"2017","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0160","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/his.13090","article-title":"Iatrogenic changes in the urinary tract","volume":"70","author":"Lopez-Beltran","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2016.10.011","article-title":"Cyclophosphamide promotes the proliferation inhibition of mouse ovarian granulosa cells and premature ovarian failure by activating the lncRNA-Meg3-p53-p66Shc pathway","volume":"596","author":"Xiong","year":"2017","journal-title":"Gene"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0170","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/0006-2952(79)90222-3","article-title":"cyclophosphamide cystitis \u2013 identification of acrolein as the causative agent","volume":"28","author":"Cox","year":"1979","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0175","first-page":"659","article-title":"Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide","volume":"29-1","author":"Brock","year":"1979","journal-title":"Arzneim.-Forsch"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0180","first-page":"37","article-title":"Structure dynamics of G-Protein coupled receptors","volume":"Vol. 796","author":"Vaidehi","year":"2014"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0185","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jmgm.2014.07.012","article-title":"Structure and putative signaling mechanism of Protease activated receptor 2 (PAR2) \u2212 A promising target for breast cancer","volume":"53","author":"Kakarala","year":"2014","journal-title":"J. Mol. Graphics Modell."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0190","first-page":"15","article-title":"Modeling of G protein-Coupled receptors using crystal structures: from monomers to signaling complexes","volume":"Vol. 796","author":"Gonzalez","year":"2014"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0195","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jmgm.2016.10.004","article-title":"Homology modeling of a Class A GPCR in the inactive conformation: a quantitative analysis of the correlation between model\/template sequence identity and model accuracy","volume":"70","author":"Costanzi","year":"2016","journal-title":"J. Mol. Graphics Modell."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0200","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jmgm.2007.12.003","article-title":"Binding modes of CCR5-targetting HIV entry inhibitors: partial and full antagonists","volume":"26","author":"Wang","year":"2008","journal-title":"J. Mol. Graphics Modell."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0205","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jmb.2009.07.093","article-title":"Ligand entry and exit pathways in the beta(2)-Adrenergic receptor","volume":"392","author":"Wang","year":"2009","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0210","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/jmr.1087","article-title":"Retinal release from opsin in molecular dynamics simulations","volume":"24","author":"Wang","year":"2011","journal-title":"J. Mol. Recognit."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0215","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.cplett.2016.07.059","article-title":"Predicted PAR1 inhibitors from multiple computational methods","volume":"659","author":"Wang","year":"2016","journal-title":"Chem. Phys. Lett."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0220","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1021\/acs.jcim.5b00087","article-title":"Three homology models of PAR2 derived from different templates: application to antagonist discovery","volume":"55","author":"Perry","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0225","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","article-title":"OPLS3: a force field providing broad coverage of drug-like small molecules and proteins","volume":"12","author":"Harder","year":"2016","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0230","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Sastry","year":"2013","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0235","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0240","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring: 1 Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0245","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.str.2009.10.010","article-title":"A role for a specific cholesterol interaction in stabilizing the apo configuration of the human A(2A) adenosine receptor","volume":"17","author":"Lyman","year":"2009","journal-title":"Structure"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0250","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1021\/jp003020w","article-title":"Structure and dynamics of the TIP3P, SPC, and SPC\/E water models at 298K","volume":"105","author":"Mark","year":"2001","journal-title":"J. Phys. Chem. A"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0255","first-page":"1097","article-title":"The LBFGS quasi-Newtonian method for molecular modeling prion AGAAAAGA amyloid fibrils","volume":"04","author":"Zhang","year":"2012","journal-title":"Nat. Sci."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0260","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/jcc.10402","article-title":"Partial rigid-body dynamics in NPT, NPAT and NP gamma T ensembles for proteins and membranes","volume":"25","author":"Ikeguchi","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0265","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/jcc.21237","article-title":"MILCH SHAKE an efficient method for constraint dynamics applied to alkanes","volume":"30","author":"Bailey","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0270","doi-asserted-by":"crossref","first-page":"54101","DOI":"10.1063\/1.1839571","article-title":"Gaussian split Ewald: a fast Ewald mesh method for molecular simulation","volume":"122","author":"Shan","year":"2005","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0275","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1063\/1.472005","article-title":"Molecular dynamics with multiple time scales: the selection of efficient reference system propagators","volume":"105","author":"Stuart","year":"1996","journal-title":"J. Chem. Phys."},{"year":"2006","series-title":"Scalable Algorithms for Molecular Dynamics.Simulations on Commodity Clusters","author":"Bowers","key":"10.1016\/j.jmgm.2017.08.019_bib0280"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0285","doi-asserted-by":"crossref","first-page":"10983","DOI":"10.1021\/jp982533o","article-title":"Generalized born model based on a surface integral formulation","volume":"102","author":"Ghosh","year":"1998","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0290","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jcc.20307","article-title":"What role do surfaces play in GB models? A new-generation of surface-generalized Born model based on a novel Gaussian surface for biomolecules","volume":"27","author":"Yu","year":"2006","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0295","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/prot.23106","article-title":"The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling","volume":"79","author":"Li","year":"2011","journal-title":"Proteins Struct. Funct. Bioinf."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0300","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","article-title":"OPLS3: a force field providing broad coverage of drug-like small molecules and proteins","volume":"12","author":"Harder","year":"2016","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0305","doi-asserted-by":"crossref","first-page":"11225","DOI":"10.1021\/ja9621760","article-title":"Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids","volume":"118","author":"Jorgensen","year":"1996","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0310","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10822-009-9271-6","article-title":"How accurate are continuum solvation models for drug-Like molecules?","volume":"23","author":"Kongsted","year":"2009","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0315","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1021\/ar000033j","article-title":"Calculating structures and free energies of complex Molecules:Combining molecular mechanics and continuum models","volume":"33","author":"Kollman","year":"2000","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0320","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/jcc.21666","article-title":"Assessing the performance of the molecular Mechanics\/Poisson boltzmann surface area and molecular Mechanics\/Generalized born surface area methods II. the accuracy of ranking poses generated from docking","volume":"32","author":"Hou","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0325","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/ci100275a","article-title":"Assessing the performance of the MM\/PBSA and MM\/GBSA methods: 1. the accuracy of binding free energy calculations based on molecular dynamics simulations","volume":"51","author":"Hou","year":"2011","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0330","doi-asserted-by":"crossref","first-page":"8408","DOI":"10.1021\/jp404160y","article-title":"Assessing the performance of MM\/PBSA and MM\/GBSA methods: 3. the impact of force fields and ligand charge models","volume":"117","author":"Xu","year":"2013","journal-title":"J. Phys. Chem. B."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0335","doi-asserted-by":"crossref","first-page":"16719","DOI":"10.1039\/C4CP01388C","article-title":"Assessing the performance of MM\/PBSA and MM\/GBSA methods: 4. Accuracies of MM\/PBSA and MM\/GBSA Methodologies Evaluated by Various Simulation Protocols Using PDBbind Data Set","volume":"16","author":"Sun","year":"2014","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0340","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bpc.2011.03.001","article-title":"Molecular mechanism of action for reversible P2Y(12) antagonists","volume":"155","author":"Liu","year":"2011","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0345","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1021\/jm800180e","article-title":"Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity","volume":"51","author":"Chackalamannil","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157553","article-title":"Examining the conservation of kinks in alpha helices","volume":"11","author":"Law","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0355","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2174\/092986712799320556","article-title":"Action of molecular switches in GPCRs \u2212 theoretical and experimental studies","volume":"19","author":"Trzaskowski","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0360","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev-pharmtox-032112-135923","article-title":"Structure-Function of the G-protein-Coupled receptor superfamily","volume":"53","author":"Katritch","year":"2013","journal-title":"Annu. Rev. Pharmacool. Toxicol."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0365","doi-asserted-by":"crossref","first-page":"7841","DOI":"10.3390\/ijms15057841","article-title":"Alpha-Bulges in G protein-Coupled receptors","volume":"15","author":"van der Kant","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095355","article-title":"Regulator of g protein signaling 2 (RGS2) and RGS4 form distinct G protein-Dependent complexes with protease activated-Receptor 1 (PAR1) in live cells","volume":"9","author":"Ghil","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0375","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.cellsig.2012.01.011","article-title":"Protease-activated receptor 1 (PAR1) coupling to G(q\/11) but not to G(i\/o) or G(12\/13) is mediated by discrete amino acids within the receptor second intracellular loop","volume":"24","author":"McCoy","year":"2012","journal-title":"Cell. Signal."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0380","doi-asserted-by":"crossref","first-page":"E3600","DOI":"10.1073\/pnas.1508838112","article-title":"N-linked glycosylation of protease-activated receptor-1 at extracellular loop 2 regulates G-protein signaling bias","volume":"112","author":"Soto","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0385","doi-asserted-by":"crossref","first-page":"11203","DOI":"10.1074\/jbc.M112.439950","article-title":"Transactivation of the PAR1-PAR2 heterodimer by thrombin elicits beta-Arrestin-mediated endosomal signaling","volume":"288","author":"Lin","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0390","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/blood-2016-06-720581","article-title":"Occupancy of human EPCR by protein C induces beta-arrestin-2 biased PAR1 signaling by both APC and thrombin","volume":"128","author":"Roy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0395","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1021\/acs.jctc.6b00618","article-title":"Conserved mechanism of conformational stability and dynamics in G-Protein-Coupled receptors","volume":"12","author":"Bhattacharya","year":"2016","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0400","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1023\/A:1015905822671","article-title":"Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors","volume":"15","author":"Gieldon","year":"2001","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.jmgm.2017.08.019_bib0405","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nmeth.3479","article-title":"Imaging G protein-coupled receptors while quantifying their ligand-binding free-energy landscape","volume":"12","author":"Alsteens","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.jmgm.2017.08.019_bib0410","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3109\/10799893.2014.926925","article-title":"Screening of phytochemicals against protease activated receptor 1 (PAR1), a promising target for cancer","volume":"35","author":"Kakarala","year":"2015","journal-title":"J. Recept. Signal Transduction"}],"container-title":["Journal of Molecular Graphics and Modelling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326317305077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326317305077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:56:40Z","timestamp":1761080200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1093326317305077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":82,"alternative-id":["S1093326317305077"],"URL":"https:\/\/doi.org\/10.1016\/j.jmgm.2017.08.019","relation":{},"ISSN":["1093-3263"],"issn-type":[{"type":"print","value":"1093-3263"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating detailed interactions between novel PAR1 antagonist F16357 and the receptor using docking and molecular dynamic simulations","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Graphics and Modelling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmgm.2017.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}